Drug Trial Radar · NCT06465953
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Dec 3, 2024
Primary completion
Nov 1, 2027
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Servier Bio-Innovation LLC
- First posted
- Jun 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cycle 1 (Days 1, 8, 15, and 22), and Day 1 of each cycle thereafter. After the last dose of treatment, participants will attend an safety follow-up visit and participants will be followed to assess overall survival. Study visits may include a bone marrow aspirate, physical exam, echocardiogram (ECHO), electrocardiogram (ECG), blood and urine analysis, and questionnaires.
Conditions
- Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
- Myelodysplastic Syndromes (MDS)
Interventions
IvosidenibDrug
Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
AzacitidineDrug
Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants achieving CR and PR by 4 monthsTime frame: Through 4 months after starting treatment
Locations
62 sites in 10 countries. Site status is shown where the registry gives one.
Presbyterian / St. Luke'S Medical Center
Denver, Colorado · Recruiting
University of Chicago, Duchossois Center for Advanced Medicine (DCAM)
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
MSKCC
New York, New York · Recruiting
Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Oncology Associates of Oregon
Eugene, Oregon · Recruiting
University of Texas UT Southwestern Comprehensive Cancer Center
Dallas, Texas · Recruiting
MD Anderson Cancer Centre
Houston, Texas · Recruiting
Royal Adelaide Hospital
Adelaide, Australia · Not yet recruiting
Monash Health
Clayton, Australia · Recruiting
Northern Health
Epping, Australia · Recruiting
Liverpool Hospital
Liverpool, Australia · Not yet recruiting
Sir Charles Gairdner Hospital
Nedlands, Australia · Recruiting
Calvary Mater Newcastle
Waratah, Australia · Recruiting
Liga Paranaense de Combate ao Câncer - Hospital Erasto Gaertner
Curitiba, Brazil · Recruiting
Centro de Pesquisa Clínica - Hospital Nove de Julho
São Paulo, Brazil · Recruiting
Real E Benemérita Associação Portuguesa de São Paulo
São Paulo, Brazil · Recruiting
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, Brazil · Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil · Recruiting
Casa de Saúde Santa Marcelina
São Paulo, Brazil · Recruiting
Centro de Pesquisas Clínicas da Fundação Doutor Amaral Carvalho
São Paulo, Brazil · Recruiting
Instituto Nacional do Câncer
São Paulo, Brazil · Not yet recruiting
Chu Nantes-Hotel Dieu
Nantes, France · Recruiting
Chu de Nice - Hôpital L'Archet 1
Nice, France · Recruiting
Hopital Saint Louis
Paris, France · Recruiting
Chu Bordeaux, Hopital Du Haut Leveque
Pessac, France · Recruiting
Institut Universitaire Du Cancer Toulouse-Oncopole
Toulouse, France · Recruiting
Chu Brabois
Vandœuvre-lès-Nancy, France · Recruiting
Universitatsklinikum Dresden Carl Gustav Carus
Dresden, Germany · Recruiting
Marien Hospital Duesseldorf
Düsseldorf, Germany · Recruiting
Universitaetsmedizin Goettingen (Umg)
Göttingen, Germany · Recruiting
Universitaetsklinikum Leipzig
Leipzig, Germany · Recruiting
Tum Klinikum Rechts Der Isar
Munich, Germany · Recruiting
Azienda Ospedaliero Universitaria Delle Marche
Ancona, Italy · Recruiting
Istituto Di Ematologia "Lorenzo E Ariosto Seragnoli" - Policlinico Di S. Orsola
Bologna, Italy · Recruiting
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy · Recruiting
Humanitas Research Hospital (Istituto Clinico Humanitas)
Milan, Italy · Recruiting
Fondazione I.R.C.C.S. Policlinico San Matteo
Pavia, Italy · Recruiting
Dipartimento Di Biomedicina E Prevenzione - Universita Degli Studi Di Roma "Tor Vergata"
Roma, Italy · Recruiting
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.